Remimazolam
NERVOUS SYSTEM
Also known as: anerem, aptimyda, byfavo, CNS 7056, CNS 7056B, ONO-2745, ONO-2745BS, remimazolam besylate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Remimazolam is an ofp drug catalogued in DrugCentral. It was first approved by the PMDA in 2020. DrugCentral lists 5 molecular targets, including GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3, Gabrg2|Gabra1|Gabrb2 and Gabrg2|Gabra2|Gabrb2. Recorded indications include Sedation.
- Approval status: ofp (first approved 2020 by the PMDA).
- Molecular targets: GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3, Gabrg2|Gabra1|Gabrb2, Gabrg2|Gabra2|Gabrb2 and Gabrg2|Gabra3|Gabrb2 (5 listed in DrugCentral).
- Indications: Sedation.
- ATC code: N05CD14 (Benzodiazepine derivatives).
- Molecular formula: C21H19BrN4O2; molecular weight 439.31 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Sedation
Contraindications (1)
- Non-allergic hypersensitivity to dextran
Mechanism & targets
Molecular targets (5)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA-A receptor; benzodiazepine binding site | GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3 | modulator | Ki 7.53 |
| GABA-A receptor; alpha-1/beta-2/gamma-2 | Gabrg2|Gabra1|Gabrb2 | modulator | EC50 6.44 |
| GABA A receptor alpha-2/beta-2/gamma-2 | Gabrg2|Gabra2|Gabrb2 | modulator | EC50 6.18 |
| GABA A receptor alpha-3/beta-2/gamma-2 | Gabrg2|Gabra3|Gabrb2 | modulator | EC50 6.04 |
| GABA A receptor alpha-5/beta-2/gamma-2 | Gabra5|Gabrb2|Gabrg2 | modulator | EC50 5.86 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-03-26 | EMA | — | PAION Netherlands B.V. | |
| 2020-07-02 | FDA | — | ACACIA | |
| 2020-01-23 | PMDA | — | Anerem |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N05CD14 | NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Benzodiazepine derivatives |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Anaphylactic shock | 109.8 |
| Vascular access site occlusion | 105.5 |
Chemical structure
| Molecular formula | C21H19BrN4O2 |
|---|---|
| Molecular weight | 439.31 g/mol |
| CAS number | 308242-62-8 |
| InChIKey | CYHWMBVXXDIZNZ-KRWDZBQOSA-N |
| PubChem CID | 9867812 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Remimazolam used for?
DrugCentral lists the following indications for Remimazolam: Sedation.
How does Remimazolam work?
Its molecular targets in DrugCentral include GABRA1|GABRA2|GABRA3|GABRA5|GABRG1|GABRG2|GABRG3 (modulator), Gabrg2|Gabra1|Gabrb2 (modulator), Gabrg2|Gabra2|Gabrb2 (modulator) and Gabrg2|Gabra3|Gabrb2 (modulator).
When was Remimazolam first approved?
Remimazolam was first approved by the PMDA in 2020.
What is the chemical formula of Remimazolam?
Remimazolam has the molecular formula C21H19BrN4O2 and a molecular weight of 439.31 g/mol.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5400 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4297526 — compound record and bioactivity
- PubChem CID 9867812 — chemical identifiers
- DrugBank DB12404 — drug record
- FDA UNII 7V4A8U16MB — substance identity
- DailyMed: FDA labels for Remimazolam — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.